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Abstract
Background: The prevalence and impact of antimicrobial “allergy” labels and Adverse Drug Reactions (ADRs) on
antibiotic usage and antimicrobial stewardship initiatives is ill defined. We sought to examine the rate of antimicrobial
“allergy labels” at our tertiary referral centre and impacts on antimicrobial usage and appropriateness.
Methods: Two inpatient antimicrobial prevalence surveys were conducted over a 1-week period in November 2013
and 2014 as part of the prospective National Antimicrobial Prescribing Survey (NAPS). Post survey, patients recorded in
the NAPS database were assigned to two groups based upon recorded antimicrobial “allergy label” and ADR:
(i) Antimicrobial Allergy/ADR (AA) or (ii) No Antimicrobial Allergy/ADR (NAA). Antimicrobial usage and antimicrobial
appropriateness were compared between AA and NAA groups.
Results: From 509 identified patients the prevalence of an antimicrobial allergy or ADR was 25 %. The prevalence of
“allergy labels”/ADR was 10 % (51/509) for penicillin V/G, 5 % (24/509) cephalosporins, 4 % (22/509) trimethroprim-
sulfamethoxazole and 3 % (17/509) aminopenicillins. One thousand and seventy antimicrobials were prescribed during
the study periods, the median antimicrobial duration was longer in the AA versus NAA group (6 days vs. 4 days;
p = 0.018), and proportion of inappropriate antimicrobial prescribing higher in the AA group compared with NAA
(29 %; 35/120 vs. 23 %; 86/367, p = 0.22). Oral antimicrobial administration was higher in the NAA than AA group
(60 %; 177/297 vs. 46 %; 356/793, p = 0.0001). The proportion of patients that received a β-lactam was lower in
the AA versus NAA group (60 % vs. 79 %, p = 0.0001).
Conclusions: In an Australian tertiary referral centre an antimicrobial “allergy” or ADR label was found to
significantly impacted on rate of oral antimicrobial administration, beta-lactam usage, antimicrobial duration and
antimicrobial appropriateness.
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Background
Antimicrobial “allergy labels” describing Adverse Drug
Reactions (ADRs) are frequently reported. Traditionally,
antimicrobials have been known to elicit both Type A
ADRs (non-immune mediated) and Type B ADRs (immune
mediated), the later typically avoided due to fear of pheno-
typic recurrence [1, 2]. However the prevalence and impact
of antimicrobial Type A and B ADRs is not well defined.
Despite the varied pathogenesis of antimicrobial ADRs, the
approach to antimicrobial allergy labeling is often the same
[3, 4]. The impact antimicrobial ADRs have on antimicro-
bial stewardship, prescribing, infectious diseases practice
and restricted antimicrobial usage is relatively unknown [5].
Utilizing an Australian National Antimicrobial Prescribing
Survey (NAPS) prospective database we estimate the preva-
lence of antimicrobial “allergy labels” and ADRs in an Aus-
tralian inpatient tertiary hospital population receiving
antimicrobial therapy. We describe the commonly impli-
cated antimicrobials in ADRs and allergy descriptions.
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Furthermore, we assess the impact of antimicrobial “allergy
labels” and ADRs on antimicrobial appropriateness and
restricted antimicrobial usage.
Methods
The study was performed at The Alfred hospital, a 350-
bed tertiary referral center. Two prevalence surveys were
conducted over a 1 week period in November 2013 and
2014 as part of the prospective National Antimicrobial
Prescribing Survey (NAPS) [6]. The NAPS was devel-
oped in 2011 to assess Australian health care facility
antimicrobial prescribing practices. The NAPS identifies
inpatients receiving antimicrobial therapy during the
prevalence periods, prospectively recording patient anti-
microbial usage (agent, dose, frequency, route, duration)
and baseline demographics (age, sex, admitting unit,
allergy history), infection history (infective diagnosis)
and antimicrobial appropriateness score. The NAPs cap-
tures recorded patient antimicrobial “allergies” and
ADRs from medical records and/or drug charts.
After NAPS data collection patients were assigned to
one of two groups based upon the presence of a re-
corded antimicrobial “allergy label” or ADR: (i) Anti-
microbial Allergy/ADR (AA) or (ii) No Antimicrobial
Allergy/ADR (NAA). Study investigators JAT and JAE
independently defined patient AA description(s) as per
published definitions as either likely (i) Type A, (ii) Type
B (Class I – IV), or (iii) Unspecified (U) [7].. When con-
sensus could not be reached a third study investigator
was recruited for a tie-breaking vote. Antimicrobial
usage and antimicrobial appropriateness were compared
between AA and NAA groups.
An infectious diseases physician defined antimicrobial
appropriateness according to NAPS criteria: 1 (optimal),
2 (adequate), 3 (suboptimal), 4 (inadequate) or 5 (not as-
sessable) [6]. A score of one or two was considered to be
‘appropriate’ and three or four as ‘inappropriate’.
A Type A ADR was defined as a non-immune medi-
ated reaction that relates to the predictable pharmaco-
logical properties of a drug. A Type B ADR was defined
as an immune mediated reaction that does not related to
the predictable pharmacological properties of a drug [1].
This was subcategorized into one of four classes: (i) Im-
mediate (IgE), (ii) accelerated or delayed (Cytotoxic
IgG), (iii) accelerated or delayed (Immune complex IgG)
and (iv) Delayed (T cell-mediated) [2, 7]. The duration
of antibiotic therapy was the number of days from the
recorded commencement of antibiotic therapy until the
date of the survey. For this study, restricted broad-
spectrum antibiotic was defined as a carbapenem,
fluoroquinolone or glycopeptide antibiotic. ‘De-labeling’
is defined as the removal or revision of an antibiotic al-
lergy label following clinical allergy assessment and/or
allergy testing or re-challenge [5]. Alfred Health Human
Research Ethics Committee approval was obtained for
NAPS data collection.
Statistical analysis
Categorical variables were summarized using frequency
and percentage and compared between groups using a
chi-square test. Continuous variables were summarized
using mean and standard deviation (SD) or median and
inter-quartile range as appropriate and compared using
a paired t-test or Wilcoxon signed-rank test as appropri-
ate. A univariate negative binomial regression model was
utilized, a variant of a poisson regression allowing for
over-dispersion, to test the null hypothesis of no differ-
ence in cumulative days of antimicrobial exposure be-
tween groups. Standard errors were estimated using the
robust Huber White sandwich estimator.
Results
We identified 509 patients according to NAPS inclusion
criteria from the combined point prevalence periods, 245
from 2013 and 264 from 2014. The baseline cohort demo-
graphics are outlined in Table 1. Twenty-five percent (128/
509) of patients identified in the NAPs database had a doc-
umented report of “antimicrobial allergy” or ADR (AA).
The prevalence of “allergy labels”/ADR was 10 % (51/509)
for penicillin V/G, 5 % (24/509) cephalosporins, 4 % (22/
509) trimethroprim-sulfamethoxazole/sulphonamide anti-
biotics and 3 % (17/509) aminopenicillins. The distribu-
tion of patients between admitting units was similar in
the AA and NAA groups (p = 0.58), however a higher
male predominance in the NAA versus AA group was
noted (66 % vs. 49 %, p = 0.007).
Antimicrobial allergy descriptions
In the 128 patients reporting one or more allergies/
ADRs, there were 202 antimicrobial allergies and ADRs
recorded in the allergy record for the 128 patients. Of
these 202 antimicrobials, 102 (50 %) were considered
likely Type B, 48 (24 %) Type A, 51 (25 %) unspecified
and 1 % anaphylactoid (2/202). Of those Type B ADRs,
39 % (40/102) had clinical findings consistent with Class
I (immediate) reactions and 61 % (62/102) Class IV (de-
layed). Fifty-four percent (109/202) of reported anti-
microbial ADRs were toward a β-lactam, 62 % (67/109)
Type B, 17 % (19/109) Type A and 21 % (23/109) un-
specified. The complete list of antimicrobial allergies
and reported ADRs are demonstrated in Table 2.
Antimicrobial usage and appropriateness
From the 509 patients, 1070 antimicrobials were pre-
scribed during the study periods, 297 for the AA group
versus 773 for the NAA group. The top five antimicro-
bial agents administered for the AA and NAA groups
are displayed in Table 3. The median antimicrobial
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duration was longer in the AA versus NAA group (6 days
vs. 4 days; p = 0.018), whilst there was a non-significant
increase in the proportion with inappropriate antimicro-
bial prescribing in the AA group compared with NAA
(29 %; 35/120 vs. 23 %; 86/367, p = 0.22). Oral antimicro-
bial administration was higher in the NAA than AA
group (60 %; 177/297 vs. 46 %; 356/793, p = 0.0001). The
proportion of patients that received a β-lactam or ceph-
alosporin was lower in the AA versus NAA groups, 60 %
vs. 79 % (p = 0.0001) and 24 % vs. 43 % (p = 0.05) re-
spectively. There was no difference in the proportion of
AA versus NAA patients that received a restricted anti-
microbial, 25 % vs. 24 % (p = 0.44). Sixty three percent
(56/89) of patients reported to be allergic to at least one
β-lactam still received a β-lactam antibiotic.
It was estimated that the AA compared to NAA pa-
tients had a non-statistically significant 38 % increase in
antimicrobial days exposure (R 0.328, 95 % CI-0.72–
0.72, p = 0.11) and 31 % increase in antibiotic days ex-
posure (R 0.27, 95 % CI:-0.14–0.68, p = 0.19).
Discussion
By utilizing single center data from the NAPS survey, we
were able to demonstrate a high prevalence of total anti-
microbial “allergy labels” and ADRs (25 %) in our mixed
inpatient population receiving antimicrobial therapy,
55 % of which were consistent with a non-immediate
reaction. Our findings are broadly consistent with other
reported international studies, but with some interest-
ing differences. We found a quarter of patients had
been labeled as having an “allergy” which is at the
higher end of previously reported studies [5, 8, 9].
Charneski et al. demonstrated in a large group of gen-
eral medical and surgical patients that 11 % had an
antimicrobial “allergy label” [3]. Lee et al. revealed 25 %
antibiotic allergy prevalence, however with a higher
rate of immediate reactions than illustrated in our co-
hort (32 % vs. 20 %) [10].
Identifying patients with either known drug side ef-
fects (Type A) or non-severe delayed reactions (Type
B) may potentially allow for supervised re-challenge to
aid appropriate antimicrobial therapy [11]. However, re-
cent reports suggest this definition may require re-
evaluation, as Type A reactions may in fact be dose
dependent and genetically predisposed, whilst Type B
in some cases non-immune mediated (e.g. non-IgE me-
diated mast cell activation by fluoroquinolones) [1, 12,
13]. Nonetheless, we identified that 54 % of our study
population have likely non-immediate ADRs, highlighting
a potential for direct re-challenge and “de-labeling” in
those unlikely to be genetically predisposed [14]. β-lactams
are often the preferred therapy in many invasive infections,
Table 1 Baseline demographics for NAPS cohort (2013-2014)
Cohort demographics AA NAA Total
N = 128 N = 381 N = 509
Age (years)
Median 58 59 59
Sex
Male 63 (49) 252 (66) 315 (61)
Admitting Unit
Specialist medical 73 (57) 160 (42) 233 (46)
General medical 23 (18) 40 (11) 63 (12)
General surgical 6 (5) 31 (8) 37 (7)
Specialty surgical 25 (2) 147 (39) 172 (34)
Othera 1 (1) 3 (1) 4 (1)
Immunosuppressedb
Yes 33 (26) 76 (20) 109 (21)
Total drug allergies 128 (100) 5 (1) 133 (26)
Total antimicrobials administered 297 773 1070
Route of antimicrobial administration (n = 1070)
Oral 177(60) 356 (46) 533 (50)
Intravenous 102 (34) 371 (48) 473 (44)
Otherc 18 (6) 46 (6) 64 (6)
aEmergency (3), Intensive care unit (1)
bHaematology, oncology, lung and heart transplant units
cInhaled, topical
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yet often avoided due to a distant history of non-
immediate allergy or Type A ADR. The lower uptake of β-
lactams in our NAA group may be potentially addressed
in the future by direct re-challenge or formal SPT/IDT
programs[14]. Clinical programs that have utilized anti-
biotic re-challenge in ‘low risk’ phenotypes, predominately
‘unknown’ or Type A ADRs, have demonstrated an in-
crease in β-lactam usage post implementation [15]. Inter-
estingly, 60 % of our patients with a β-lactam “allergy”
received a β-lactam; the resultant proportion that was sub-
sequently “de-labeled” is unclear. The importance of “de-
labeling” strategies is strengthened by studies that have
highlighted that an antibiotic “allergy label” is associated
with increased costs, antibiotic exposure and resistant or-
ganism generation [4, 5, 16].
This study is limited by small study numbers, recall
bias of true ADR descriptions by patients and assess-
ment of prescribing over short study periods. Whilst
clarification of which patients had “mislabeled” AA
would be preferred, the fact that most clinicians are
known to act upon these labels without clarification is
significant [17]. The study does highlight the need for
both a better understanding, as well as a management
strategy to assess patients with antimicrobial allergy/
ADR “labels”. Although the study had limited power to
determine differences in prescribing practices, ciproflox-
acin was the most frequently used antimicrobial in the
AA group and meropenem was represented in the “top
5”, albeit with no appreciable difference in restricted
antimicrobial usage between the groups. Inappropriate
prescriptions were more frequently identified in AA pa-
tients, and although not statistically significant, this ‘sig-
nal’ requires further evaluation in larger cohorts.
Furthermore, the AA group had an increased exposure
to antimicrobials (i.e. duration), which we intend to also
explore more fully in a larger dataset.
Conclusion
We identified an antimicrobial “allergy label” prevalence
of 25 % in our tertiary referral center, 10 % for a penicil-
lin “allergy label”. The majority of adverse drug reactions
recorded were against β-lactams (50 %), with a predom-
inance of non-immediate ADRs. The high rate of β-






































aPenicillin – Penicillin V, Penicillin G. bKetoconazole, fluconazole, voriconazole
cQuinine (1), Linezolid (1), Amphoterician (1), clotrimazole (1), Rifampacin (1),
terbinafine (1)
Table 3 The most frequent antimicrobials used (in order) for




1 Ciprofloxacin 15 (5 %)
2 Cephazolin 13 (5 %)
3 Ceftazadime 12 (4 %)
4 Ceftriaxone 11 (4 %)
5 Meropenem 10 (4 %)
NAA group
(n = 792)
1 Cephazolin 69 (9 %)
2 Ceftriaxone 59 (7 %)
3 Piperacillin-tazobactam 47 (6 %)
4 Ciprofloxacin 40 (5 %)
5 Amoxicillin – clavulanate 33 (4 %)
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lactam use in patients with a β-lactam “label” raises
questions about the validity of these ADRs and/or pres-
ence of a selective side chain allergy. A higher amount
of intravenous antimicrobial administration and trend
toward increased inappropriate antimicrobial prescrip-
tion in the AA group was also noted. Further assessment
of the entire NAPS database, paying particular attention
to the highest users of antimicrobial therapy (i.e. im-
munosuppressed) may further clarify if the differences
seen in antimicrobial exposure are significant.
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